The FDA recently announced that it will begin offering faster drug reviews to certain medicines, reducing the drug review process from approximately ten months to one or two months. This news follows a series of rapid changes from the FDA since the Trump administration took office.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Amy Bucher, chief behavioural officer at Lirio, a healthcare personalization platform helping insurers, health systems, and pharmacies deliver precision nudges to move patients into action.

Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective, as well as how regulatory changes, such as fast-tracking drug approvals as seen with the FDA lately, can impact patient perception.

You can listen to episode 234 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.